Haemonetics (HAE) Amortization of Deferred Charges (2012 - 2024)

Haemonetics' Amortization of Deferred Charges history runs 9 years deep, the most recent figure standing at $782000.0 for Q1 2024.

• On a quarterly basis, Amortization of Deferred Charges fell 10.32% year-over-year to $782000.0 in Q1 2024; TTM through Mar 2024 was $3.2 million, a 61.17% increase from a year earlier, with the FY2024 full-year figure at $3.2 million, up 61.17% from the prior year.
• Amortization of Deferred Charges held at $782000.0 in Q1 2024 per HAE's latest filing, from $783000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $1.0 million in Q3 2021 and bottomed at -$484000.0 in Q4 2022.
• The 5-year median for Amortization of Deferred Charges is $789500.0 (2021), against an average of $630500.0.
• Biggest YoY gain for Amortization of Deferred Charges was 472.66% in 2022; the steepest drop was 160.96% in 2022.
• Year by year, Amortization of Deferred Charges stood at $139000.0 in 2020, then surged by 471.22% to $794000.0 in 2021, then declined by 1.13% to $785000.0 in 2022, then declined by 0.25% to $783000.0 in 2023, then fell by 0.13% to $782000.0 in 2024.
• Per Business Quant, the three latest HAE Amortization of Deferred Charges figures stand at $782000.0 (Q1 2024), $783000.0 (Q4 2023), and $780000.0 (Q3 2023).